Endosane

Overview
Endosane, registered as Endosane Pharmaceuticals GmbH, is a Berlin-headquartered German pharmaceutical company, incorporated in 2021 as a joint venture of Berlin-based cannabinoid-therapeutics and consumer group Sanity Group and an international research team led by Prof. Dr. F. Markus Leweke and Dr. Cathrin Rohleder. Endosane develops drug candidates targeting the endocannabinoid system for neuropsychiatric and psychiatric disorders, with a historical lead programme in schizophrenia and a preclinical set for post-traumatic stress disorder announced in August 2026 with the University of California Irvine. Endosane operates as a subsidiary of Sanity Group, which was acquired by Canadian cannabis operator Organigram Global in 2026.

Why this entity matters
Endosane is a T2-plus reference entity for the DACH biotech, mental-health-drug-development and cannabinoid-therapeutics narrative for four reasons. First, the endocannabinoid system remains one of the most clinically under-exploited neuromodulatory systems in psychiatry, and Endosane's scientific team includes Prof. Dr. F. Markus Leweke, whose earlier work on cannabidiol in schizophrenia is among the most-cited investigator studies in the field, giving the company a rare depth of investigator-led evidence for its drug-target thesis. Second, Endosane is one of a small number of German biotechs pursuing a schizophrenia programme at the clinical-development stage, in a category where the last novel antipsychotic mechanisms of action reached the market a very long time ago and where unmet medical need remains structurally high. Third, Endosane's corporate architecture as a Sanity Group subsidiary connects the company to one of Europe's most-funded cannabinoid consumer-and-therapeutic platforms and to Sanity Group's 2022 USD 37.6 million Series B, and the 2026 acquisition of Sanity Group by Canadian cannabis operator Organigram Global places Endosane inside a listed-company perimeter. Fourth, Endosane's August 2026 University of California Irvine research partnership on post-traumatic stress disorder is a live public-domain data point confirming that the company remains active despite earlier rumours in the German biotech press suggesting the programme had wound down.

Company history and product
Endosane Pharmaceuticals GmbH was incorporated in 2021 in Berlin as a joint venture of Sanity Group and an international research team led by Prof. Dr. F. Markus Leweke and Dr. Cathrin Rohleder. The founding scientific thesis was to systematically exploit the endocannabinoid system - the family of endogenous lipid-based neuromodulators and their receptors - as a next-generation drug target for neuropsychiatric and psychiatric disorders, with a specific historical focus on schizophrenia. Prof. Dr. F. Markus Leweke's earlier investigator work on cannabidiol as a potential antipsychotic is among the most-cited neuropsychopharmacology studies in the field, and Endosane's programme narrative from launch was framed around resuming and extending an advanced clinical programme (widely reported as Phase II-stage work) in schizophrenia. Endosane operates as a subsidiary of Sanity Group, whose institutional and celebrity backers have historically included Casa Verde Capital, Navy Capital, Redalpine, HV Capital, Calyx, Cherry Ventures, Bitburger Ventures, SOJE Capital and business angels including Will.i.am, Scooter Braun, Alyssa Milano and Mario Gotze; Sanity Group announced a USD 37.6 million Series B in September 2022 which was widely described at the time as one of Europe's largest cannabis-related venture rounds. In August 2026 Endosane and the University of California Irvine announced a set of preclinical studies to investigate two novel compounds for post-traumatic stress disorder, extending Endosane's pipeline beyond schizophrenia. In 2026 Canadian cannabis operator Organigram Global completed the acquisition of Sanity Group, and former Endosane Managing Director Max Narr joined the Organigram board of directors. Nothing in this record is intended as investment advice, medical advice or as an evaluation of any particular therapeutic or investment claim.

Role in the DACH startup and technology ecosystem
Endosane sits at the intersection of three DACH themes. First, it is one of the highest-profile German biotech ventures at the intersection of the endocannabinoid-system-targeted-therapeutics category and the classical DACH biotech ecosystem, complementing coverage of adjacent Berlin biotech ventures. Second, it is one of a small number of German mental-health-drug-development programmes at the clinical stage in schizophrenia, in a category where structural unmet need is very high and the pace of novel mechanism-of-action approvals has been very slow. Third, it is a canonical example of the venture-plus-listed-company transition pathway in cannabinoid-adjacent biotech: an investigator-led German joint venture originally scaffolded inside a well-funded venture-backed European cannabinoid platform (Sanity Group), and subsequently rolled into a listed North American cannabis operator (Organigram Global) via the 2026 Sanity Group acquisition.

Selected relationships and affiliations
Co-founding scientific principals: Prof. Dr. F. Markus Leweke; Dr. Cathrin Rohleder. Corporate parent: Sanity Group (Berlin). Ultimate parent from 2026: Organigram Global (Canada). Former Managing Director: Max Narr (joined the Organigram board of directors following the 2026 acquisition). Headquarters: Berlin, Germany. Research partner (August 2026): University of California Irvine (preclinical PTSD compound set). Sanity Group historical institutional investors (rolling up to Endosane via parent-company economics only): Casa Verde Capital; Navy Capital; Redalpine; HV Capital; Calyx; Cherry Ventures; Bitburger Ventures; SOJE Capital. Sanity Group historical business-angel and celebrity backers: Will.i.am; Scooter Braun; Alyssa Milano; Mario Gotze. Related Startuprad.io entities: Sanity Group; Kranus Health and other DACH mental-health-technology coverage; Berlin biotech coverage.

Startuprad.io relevance
Endosane is a T2 reference entity for Startuprad.io's DACH biotech, mental-health-drug-development and cannabinoid-therapeutics coverage. Startuprad.io has one verified tagged reference to Endosane, in a founder-interview context, anchored by the Endosane founder interview with Max Narr and set alongside Startuprad.io's broader Sanity Group coverage.

Public source context
This profile draws on Endosane's own website https://www.endosane.de , the Sanity Group joint-venture announcement https://sanitygroup.com/en/2021/10/05/sanity-group-joins-medicinal-cannabis-europe-as-executive-board-member%E2%80%8B/ , the Sanity Group Series B release https://sanitygroup.com/en/2022/09/27/press-release-sanity-group-announces-series-b-funding-round/ , the Sanity Group and Organigram Global acquisition-closing release https://sanitygroup.com/en/2026/04/16/organigram-global-and-sanity-group-announce-successful-closing-of-acquisition/ , the Sanity Group announcement of the Organigram transaction https://sanitygroup.com/en/2026/02/18/sanity-group-becomes-part-of-canadian-cannabis-market-leader-organigram-global-to-drive-international-growth/ , the Cannabiz coverage of the joint venture https://www.cannabiz.com.au/german-joint-venture-targets-endocannabinoid-system-to-treat-schizophrenia-and-anxiety/ , the C and EN feature on psychedelic-and-cannabinoid pharma https://cen.acs.org/pharmaceuticals/drug-development/Drug-companies-investing-big-psychedelics/100/i9 , the Cannabis Science and Technology report on the University of California Irvine partnership https://www.cannabissciencetech.com/view/endosane-pharmaceuticals-and-the-university-of-california-irvine-to-conduct-a-set-of-studies-to-investigate-new-compounds-for-treatment-of-post-traumatic-stress-disorder , the CB Insights company page https://www.cbinsights.com/company/endosane-pharmaceuticals , the Psychedelic Alpha directory https://psychedelicalpha.com/resources/psychedelic-companies-directory/ , and Startuprad.io's own founder interview with Max Narr.

Startuprad.io coverage of Endosane

Endosane appears in the following Startuprad.io coverage, verified live against the Startuprad.io blog archive at time of publication.

Endosane Brings New Hope For Patients With Mental Health Conditions — Founder Interview
Published: 15 March 2026
Last updated: 26 August 2026
Coverage type: Interview
https://www.startuprad.io/post/endosane-brings-new-hope-for-patients-with-mental-health-conditions-founder-interview

About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.


### §24.4.1 Startuprad.io Coverage

coverage_count: 3
coverage_last_updated: 2026-09-16

1. Endosane Brings New Hope For Patients With Mental Health Conditions — Founder Interview — 2026-03-15
https://www.startuprad.io/post/endosane-brings-new-hope-for-patients-with-mental-health-conditions-founder-interview
2. Meet Kranus Health — Founder Interview — 2026-03-15
https://www.startuprad.io/post/an-english-world-premiere-meet-kranus-health-the-startup-behind-germany-s-most-successful-digita
3. Blue Forest Ventures — 2024-06-13
https://www.startuprad.io/post/blue-forest-ventures-transforming-scientific-research-into-marketable-solutions

For DACH operators tracking Endosane and its market, Vault-only briefings cover cap-table dynamics, product-signal tracking and the monthly read on the DACH peer set.
▶ YouTube Membership: https://www.youtube.com/startupradio/join
✉️ Substack: https://startupradio.substack.com/subscribe

Canonical record: https://www.startuprad.io/entities/endosane